Suzano S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports the unaudited condensed consolidated interim financial information for Suzano S.A. for the nine-month period ended September 30, 2025. Suzano is a global leader in the production of hardwood pulp, paper, and consumer goods (tissue), with operations primarily in Brazil and the United States. The company operates 16 industrial units and manages significant biological assets (eucalyptus forests).
Key Financial Metrics
| Metric (R$ in thousands) | 9 Months Ended Sep 30, 2025 | 9 Months Ended Sep 30, 2024 |
|---|---|---|
| Net Sales | 37,001,961 | 33,226,284 |
| Gross Profit | 12,210,909 | 14,585,474 |
| Operating Profit (Pre-Net Financial) | 7,103,714 | 11,275,271 |
| Net Income (Attributable to Controlling) | 13,298,971 | (330,540) |
| Adjusted EBITDA | 16,153,488 | 17,368,281 |
| Cash Provided by Operating Activities | 12,792,522 | 14,401,553 |
| Cash and Cash Equivalents (End of Period) | 15,838,866 | 5,818,031 |
| Total Debt (Loans, Financing, Debentures) | 92,962,205 | 101,435,531 |
| Net Financial Result | 13,172,959 | (13,245,961) |
Note: All figures are in thousands of Brazilian Reais (R$). The significant swing in Net Income is largely driven by financial results.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by approximately 11.4% year-over-year, driven by higher volumes and pricing, particularly in the Pulp segment (R$27.9B vs R$26.4B).
- Profitability Surge: The company reported a Net Income of R$13.3 billion, a dramatic turnaround from a Net Loss of R$330 million in the same period of 2024. This is primarily attributable to a massive positive Net Financial Result of R$13.2 billion, compared to a negative R$13.2 billion in 2024.
- Financial Drivers: The financial result was boosted by R$9.5 billion in monetary and exchange variations (beneficial impact of Real appreciation against USD on net debt) and R$7.4 billion in gains from derivative financial instruments.
- Operating Performance: Operating profit before net financial income decreased to R$7.1 billion from R$11.3 billion, reflecting higher costs of sales and operating expenses, partially offset by lower losses from associates.
- Liquidity: Cash and cash equivalents increased significantly to R$15.8 billion from R$5.8 billion, supported by strong operating cash flow and net debt reduction.
- Debt Reduction: Total loans, financing, and debentures decreased by approximately R$8.5 billion to R$93.0 billion.
Guidance, Outlook, and Risks
- Major Acquisition: On June 5, 2025, Suzano announced an agreement to acquire a 51% interest in a global tissue business from Kimberly-Clark for approximately US$1.734 billion (R$9.222 billion). Closing is expected by mid-2026. This transaction has not yet impacted the financial statements.
- Divestiture: The company is in the process of terminating its partnership in the joint venture Woodspin Oy and divesting its interest in Spinnova Plc, recognizing impairment losses and write-offs totaling R$181.5 million in the period.
- Financial Risk Management: The company maintains a conservative hedging policy. Sensitivity analysis indicates that a 25% depreciation of the Brazilian Real against the US Dollar would negatively impact profit or loss by approximately R$17.3 billion on loans and financing, though this is partially offset by derivative positions.
- Legal Contingencies: The company maintains provisions for judicial liabilities totaling R$2.8 billion. Significant contingencies with possible losses (not provisioned) total R$11.5 billion, primarily related to tax and civil lawsuits.
- Tax Environment: The company is subject to OECD Pillar Two rules in certain jurisdictions and Brazil's Additional Social Contribution on Net Income (CSLL) effective 2025. Management anticipates no material impact on financial statements based on current calculations.
Investor Verification Checklist
- Financial Result Sustainability: Verify the sustainability of the R$13.2 billion net financial gain, which is heavily dependent on exchange rate fluctuations (Real appreciation) and derivative mark-to-market valuations.
- Operating Margin Pressure: Analyze the decline in Operating Profit (pre-financial) and Adjusted EBITDA despite revenue growth, focusing on rising cost of sales and logistics expenses.
- Kimberly-Clark Transaction: Monitor the regulatory approval process and closing timeline for the US$1.7 billion tissue business acquisition.
- Debt Maturity Profile: Review the maturity schedule of the R$93 billion debt portfolio, noting significant foreign currency exposure (USD, CNY) and interest rate risks (SOFR, CDI).
- Legal Exposure: Assess the potential impact of the R$11.5 billion in unprovisioned legal contingencies, particularly the Public Civil Action regarding highway damages.